Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: calcium Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of Various Cannabinoids on Sleep Quality

NCT07769164
View directory record Official record
Conditions
Sleep Disturbance, Sleep Quality
Interventions
2 mg THC + 2 mg CBN + 2 mg CBG + 10 mg CBD + 1 mg Melatonin, 10 mg THC + 5 mg CBN + 5 mg CBG + 20 mg CBD, 10 mg THC + 20 mg CBN + 5 mg CBG, Stay Asleep Placebo, Fast Asleep Placebo
Dietary Supplement
Lead sponsor
Cannabis Science Innovations, LLC
Industry
Eligibility
21 Years to 55 Years
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01246063
View directory record Official record
Conditions
Multiple Myeloma
Interventions
carfilzomib, pegylated liposomal doxorubicin (PLD), Dexamethasone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Community Ambulation After Hip Fracture

NCT01783704
View directory record Official record
Conditions
Hip Fracture
Interventions
Nutrition, PUSH, PULSE
Dietary Supplement · Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
4
States / cities
Farmington, Connecticut • Baltimore, Maryland • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Sep 10, 2026, 6:14 AM EDT
Suspended No phase listed Observational

Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors

NCT01740739
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Mission Viejo, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Phase 1 Interventional

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

NCT01643499
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder, Adenocarcinoma of Unknown Primary, Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Duct Cell Adenocarcinoma of the Pancreas, Intestinal Adenocarcinoma of the Stomach, Localized Unresectable Adult Primary Liver Cancer, Metastatic Carcinoma of Unknown Primary, Metastatic Extrahepatic Bile Duct Cancer, Mixed Adenocarcinoma of the Stomach, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Newly Diagnosed Carcinoma of Unknown Primary, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage III Pancreatic Cancer, Stage IIIA Colon Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Gastric Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Gastric Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Gastric Cancer, Stage IIIC Rectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colon Cancer, Stage IVA Gallbladder Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Gallbladder Cancer, Stage IVB Rectal Cancer, Unresectable Extrahepatic Bile Duct Cancer
Interventions
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 10, 2026, 6:14 AM EDT
Terminated Phase 4 Interventional Results available

Steroids in Total Knee Arthroplasty

NCT02219581
View directory record Official record
Conditions
Postoperative Pain, Inflammation, Osteoarthritis
Interventions
Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo
Drug
Lead sponsor
Thomas L Bradbury
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Phase 4 Interventional

Dialysis Clinical Outcomes Revisited (DCOR) Trial

NCT00324571
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sevelamer hydrochloride, Calcium-based phosphate binder
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
72
States / cities
Gadsden, Alabama • Huntsville, Alabama • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

NCT05405244
View directory record Official record
Conditions
Overweight and Obesity, Eating Behavior
Interventions
Placebo, Bromocriptine-QR
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 10, 2026, 6:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Selinexor and Backbone Treatments of Multiple Myeloma Patients

NCT02343042
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
16
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 10, 2026, 6:14 AM EDT
Terminated Phase 2 Interventional Results available

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT02419469
View directory record Official record
Conditions
Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
Interventions
Cytarabine, Daunorubicin, Vincristine, Prednisone, PEG asparaginase, Ofatumumab, Rituximab, Methotrexate, Cyclophosphamide, Mercaptopurine, Doxorubicin, Dexamethasone acetate, Thioguanine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Not applicable Interventional

Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation

NCT00302627
View directory record Official record
Conditions
Transplant Bone Disease
Interventions
Pamidronate, vitamin D, Calcium Carbonate
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

NCT02135874
View directory record Official record
Conditions
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified, Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified, Recurrent Mixed Phenotype Acute Leukemia
Interventions
Clofarabine, Cytarabine, Dexamethasone, Idarubicin, Rituximab, Sorafenib, Sorafenib Tosylate, Vincristine, Vincristine Sulfate
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk

NCT04431960
View directory record Official record
Conditions
Postmenopausal Osteoporosis, Gut Microbiota, Cardiovascular Diseases
Interventions
blackcurrant (BC) extract
Drug
Lead sponsor
University of Connecticut
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 10, 2026, 6:14 AM EDT
Terminated Phase 3 Interventional Results available

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

NCT03635996
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System
Drug · Device
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Alamitos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Results available

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

NCT00887354
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Risedronate, Placebo, Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Fort Lauderdale, Florida • New Port Richey, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Oxalate and Innate Immunity in Kidney Stone Disease

NCT04051346
View directory record Official record
Conditions
Kidney Stone
Interventions
Low Oxalate Diet, High Oxalate Diet
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 10, 2026, 6:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

NCT04703842
View directory record Official record
Conditions
Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
Interventions
SRD-001, Placebo
Biological · Drug
Lead sponsor
Sardocor Corp.
Industry
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Effects of Vitamin D in Parkinson's Disease (PD)

NCT01119131
View directory record Official record
Conditions
Parkinson Disease, Accidental Falls
Interventions
Vitamin D3, calcium, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 6, 2016 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Phase 2 Interventional

Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

NCT03532139
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 10, 2026, 6:14 AM EDT
Recruiting Not applicable Interventional

Preventing Cognitive Decline by Reducing BP Target Trial

NCT05106036
View directory record Official record
Conditions
Cognitive Decline, Blood Pressure, Hypertension
Interventions
Clinical Support Decision Tool
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
70 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

NCT01531998
View directory record Official record
Conditions
Myeloma
Interventions
Lenalidomide, Bortezomib, Siltuximab, Dexamethasone, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Sep 10, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Technology-Assisted Cholesterol Trial in Consumers (TACTiC)

NCT04964544
View directory record Official record
Conditions
High Cholesterol
Interventions
5 mg rosuvastatin calcium with a Web App (combination product)
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 75 Years
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 10, 2026, 6:14 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Ortho-R® for Rotator Cuff Repair Compared With Standard of Care Rotator Cuff Repair Without Ortho-R®

NCT05333211
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Ortho-R/PRP
Drug
Lead sponsor
ChitogenX Inc
Industry
Eligibility
40 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Lauderdale, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 10, 2026, 6:14 AM EDT
Suspended Not applicable Interventional

Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients

NCT04559334
View directory record Official record
Conditions
Central Line Complication, Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Tetrasodium EDTA Catheter Lock Solution
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Months to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 10, 2026, 6:14 AM EDT